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The study of fungal prion proteins affords remarkable opportunities to elucidate both intragenic and extragenic effectors of
prion propagation. The yeast prion protein Sup35 and the selfperpetuating [PSI+] prion state is one of the best characterized
fungal prions. While there is little sequence homology among
known prion proteins, one region of striking similarity exists
between Sup35p and the mammalian prion protein PrP. This
region is comprised of roughly five octapeptide repeats of similar
composition. The expansion of the repeat region in PrP is associated with inherited prion diseases. In order to learn more about
the effects of PrP repeat expansions on the structural properties of
a protein that undergoes a similar transition to a self-perpetuating
aggregate, we generated chimeric Sup35-PrP proteins. Using
both in vivo and in vitro systems we described the effect of repeat
length on protein misfolding, aggregation, amyloid formation
and amyloid stability. We found that repeat expansions in the
chimeric prion proteins increase the propensity to initiate prion
propagation and enhance the formation of amyloid fibers without
significantly altering fiber stability.
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We recently described a novel chimeric prion system that was
designed to elucidate the consequences of one class of inherited prion
disease mutations on protein folding.1,2 We created a fusion between
the mammalian prion protein PrP and the yeast prion protein
Sup35p (Fig. 1). Sup35p is an essential translation termination factor
in yeast. Interestingly, the majority of the protein can be sequestered
into a self-propagating aggregate, the [PSI+] prion.3 Remarkably,
when yeast are grown in normal laboratory conditions, the [PSI+]
prion is not detrimental. In fact, the biological consequences of the
switch from the [psi-] non-prion state to the [PSI+] prion state may
be beneficial in terms of adaptation and evolution.4 Importantly, the
prion state of Sup35p can be readily detected in vivo by monitoring
the reduced function of the translation termination factor when the
protein is propagating as a prion aggregate.3 In addition, several
methods have been developed to not only follow the propagation
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Figure 1. Schematic representation of the yeast protein Sup35p and the
mammalian prion protein PrP highlighting the position of the oligopeptide
repeat domain (ORD). The amino acid sequence represents the consensus
for a single repeat. Numbers shown represent the amino acid position of
the beginning and the end of each ORD. The numbers above the schematic
represent the original PrP amino acid positioning and the numbers below
represent the original Sup35p amino acid sequence positions.

of the prion, but also to control the propagation and promote prion
induction and loss (curing).5 Therefore, in addition to simply being
a fascinating biological problem in of itself, the [PSI+] prion in yeast
affords the ability to further elucidate both intragenic and extragenic
effectors of prion biology.
Several prions have now been identified and interestingly, there is
little sequence homology between the proteins to suggest that only
one type of sequence can form a self-propagating aggregate.6-8 In
vitro studies suggest that many proteins can form amyloids under
the appropriate conditions.9 The fact that only a small percentage of
proteins propagate as prions in vivo may be partly a consequence of
physiological conditions being adequate to promote amyloid formation with those particular sequences. It is unclear what the precise
distinction between prion and amyloid is at this time, but localization alone may preclude some amyloidogenic proteins from being
“prion proteins” per se.10
The sequence context that permits a protein to adopt a prion
conformation in vivo is unclear. Several of the identified prion
proteins have a domain that is enriched in glutamine and asparagine
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In our in vivo study,1 we highlighted a unique feature of the
longest Sup35-PrP chimera that related to the ability of the protein
to adopt multiple self-perpetuating prion conformations more readily
than wild type Sup35p. We suggest that this may be an important
aspect of prion biology as it relates to inherited disease. If the repeatexpanded proteins can adopt multiple conformations that aggregate,
then that may contribute to the large amount of variation observed
in pathology and disease progression in this class of inherited prion
diseases.21,22
We also found that the spontaneous conversion of the repeatexpanded Sup35-PrP chimera into a prion state was significantly
increased. However, this conversion required another aggregated
protein in vivo, the [RNQ+] prion. In vitro, the prion-forming
domain of the chimera showed a similar trend with the longer repeat
lengths enhancing the ability of the protein to form amyloid fibers.
The chimera with repeat expansions (8, 11 or 14 repeats) formed
fibers very quickly as compared to that with the wild type number
of repeats (5). While this correlates with the in vivo data in that
both systems demonstrate an increased level of conversion with the
repeat expansion, the systems are very different with respect to their
requirement for a different “seed” to initiate the prion conversion.
So, how does the [RNQ+] prion influence [PSI+]? At the moment,
that isn’t entirely clear. Susan Liebman and colleagues discovered
another epigenetic factor in yeast, [PIN+], which was important for
the de novo induction of [PSI+].23-25 Several years later, the [RNQ+]
prion26 was found to be that factor in the commonly used [PSI+]
laboratory strains, but they also found that the overexpression of
other proteins could reproduce the effect.25 Hence, [RNQ+] can
be [PIN+], and may be the primary epigenetic element that influences [PSI+] induction in yeast, but need not be in every case. Two
models were proposed to explain the ability of [RNQ+] to influence
the induction of [PSI+].25,27 One suggested that there is a direct
templating effect where the aggregated state of the Rnq1 protein in
the [RNQ+] prion serves as a seed for the direct physical association
and aggregation of Sup35p and initiates [PSI+]. The second postulated that there is an inhibitor of aggregation in cells that is titrated
out by the presence of another aggregated protein. Recent experimental evidence suggests that the templating model may explain
at least part of the mechanism of action behind the [RNQ+] prion
inducing the formation of [PSI+].28,29
Why is [RNQ+] required for the in vivo conversion of the repeatexpanded chimera that forms amyloid on its own very efficiently in
vitro? Interestingly, we found that the [RNQ+] prion per se is not
required. We overexpressed the Rnq1 protein from a constitutive
high promoter (pGPD-RNQ1) and found that Rnq1p aggregated in
the cells but did not induce the [RNQ+] prion. That is, the cells were
still [rnq-] and did not genetically transmit the aggregated state of the
protein. However, even these non-prion aggregates of Rnq1p served
to enhance the induction of the chimeric prions. Therefore, either the
[RNQ+] prion or an aggregate of Rnq1 protein is sufficient, which
is in line with previous studies that demonstrated that some proteins
that aggregate when overexpressed can also enhance the induction
of [PSI+].25 Also of note, recent data suggests that the requirement
of [RNQ+] for the induction of Sup35p aggregation in vivo can be
overcome by very long polyglutamine or glutamine/tyrosine stretches
fused to the non-prion forming domain of Sup35p.30 These fusions
may alter protein-protein interactions or destabilize the non-prion
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(Q/N) residues, but this is not true of all prion proteins.7 Our recent
study demonstrates that the Q/N character of the Sup35p prionforming domain can be significantly reduced, yet still propagate as a
prion.1 This was also found recently in another prion protein chimera
created and expressed in yeast.6 These studies suggest that the lack
of stable secondary structure may be one of the defining features of
a prion-forming domain. One of the striking sequence similarities
that does exist between two prion proteins occurs in an oligopeptide repeat region found in Sup35p and PrP.11 Previous data clearly
demonstrated that the Sup35p repeats are important for [PSI+] prion
propagation.12-15 The deletion of a single repeat from the wild type
SUP35 sequence results in the loss of normal [PSI+] prion propagation.12 Moreover, the addition of two extra repeats of Sup35p
sequence served to enhance the formation of the [PSI+] prion.13 The
expansion of the analogous repeat domain in the mammalian prion
protein PrP is associated with an inherited form of prion disease.16
Since the repeat regions of Sup35p and PrP are similar in size and
character, we wanted to determine if the Sup35p oligopeptide repeat
region could be substituted with that of PrP. Indeed, the PrP repeats
in the context of Sup35p supported the propagation of the [PSI+]
prion in yeast.1,17 Strikingly, we found phenotypic changes that
occurred in a repeat length-dependent manner that suggested that
the repeat expansions associated with disease result in an increase in
the aggregation propensity but do not necessarily dictate only one
type of aggregate structure.1
More recently, we verified some of these results in vitro.2 These
data are in agreement with other studies on the effect of repeat expansions.18,19 Taking the analysis one step further, we demonstrated that
the stability of the amyloid fibers formed with the repeat-expanded
proteins did not differ significantly. A very interesting observation
that we made was that the formation of amyloid fibers by the longest
repeat-expanded chimera (SP14NM) followed drastically different
kinetics compared to the chimera containing the wild type number
of repeats (SP5NM).2 In unseeded reactions, SP14NM did not show
a lag phase during the course of fiber formation whereas SP5NM
displayed a characteristic lag phase. Furthermore, the morphology of
the amyloid fibers visualized by EM was different between SP14NM
and SP5NM. SP14NM fibers were curvy and clumped but SP5NM
fibers were long and straight. The correlation between the kinetics
and the morphology of amyloid formation of SP14NM and SP5NM
is reminiscent of fibers formed by β2-microglobulin (β2m) protein
in different conditions.20 At pH 3.6, β2m formed curvy, worm-like
fibers with no apparent lag phase. In contrast, long, straight fibers
were formed at pH 2.5 and had a distinct lag phase. Analysis of the
β2m fibers formed at pH 3.6 using mass spectrometric techniques
identified species ranging from monomer to 13-mer. This suggested
that the fibers were formed by monomer addition. On the other
hand, oligomers larger than tetramers were not formed during
fiber formation at pH 2.5. Based on these data the authors propose
that β2m forms fibers in a nucleation-independent manner at pH
3.6, but fiber formation at pH 2.5 follows a nucleation-dependent
mechanism. We suggest that the mechanism underlying SP5NM and
repeat-expanded SP14NM fiber formation is similar to β2m fibers
formed at pH 2.5 and pH 3.6, respectively. It will be interesting to
determine if disease-associated mutations in amyloidogenic proteins
alter the pathway whereby amyloid formation occurs and how that
process plays a role in pathogenesis.
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structure of Sup35p in such a manner that the [RNQ+] prion seed
is no longer required to form [PSI+] de novo. Indeed, the nonpolymerizing state of some of the fusion proteins was shown to be
very unstable.
So, what is the important difference between our in vitro and
in vivo systems in the prion conversion? Obviously there are many
candidates. First, the full length Sup35 protein may alter the conversion properties since a large part of the molecule is the structured C
terminal domain. The C terminal domain may influence the initiation of prion propagation in vivo and that is not a factor in the in vitro
system. Second, the influences of co-translational folding and potentially some initial unfolding of the prion-forming domain are not
present since the in vitro system starts with denatured protein. Third,
the environmental influences are clearly different. The molecular
crowding effects and chaperones that are required for prion propagation in vivo are not required for the formation of amyloid in vitro.
Finally, it is unclear if amyloid structures similar to those formed with
the prion-forming domain in vitro actually exist in yeast. Certainly
there is some correlation between the structures since aggregated
Sup35 protein from [PSI+] cell lysates can seed amyloid formation
in vitro31,32 and the fibers formed in vitro can be transformed into
[psi-] cells and cause conversion to [PSI+].33 Nevertheless, we find it
interesting that the expansion of the repeat region can have a tremendous effect on amyloid formation in vitro yet still cannot overcome
the requirement for [RNQ+] for conversion in vivo. The presence
of co-aggregating or cross-seeding proteins may play a role in the
sporadic appearance or progression of neurodegenerative diseases and
the interconnected yeast prions [RNQ+] and [PSI+] may provide a
model system for elucidating the mechanism underlying such effects.
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